Structure-Driven Mechanisms and Synergistic Approaches of Polyphyllin VII in Breast Cancer Therapy

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Alaa O. Hamouda, Nadin H. Sarg, Sara I. Ibrahim, Rania Hamdy, Sameh S. M. Soliman, Hany A. Omar
{"title":"Structure-Driven Mechanisms and Synergistic Approaches of Polyphyllin VII in Breast Cancer Therapy","authors":"Alaa O. Hamouda,&nbsp;Nadin H. Sarg,&nbsp;Sara I. Ibrahim,&nbsp;Rania Hamdy,&nbsp;Sameh S. M. Soliman,&nbsp;Hany A. Omar","doi":"10.1002/ardp.70064","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Polyphyllin VII (PP7), a natural saponin derived from the rhizomes of <i>Paris polyphylla</i> (family: Melanthiaceae), possesses a unique steroidal furostane structure that contributes to its versatile pharmacological profile. It is traditionally used in Chinese medicine for treating pain, insect bites, and bleeding. PP7's unique pharmacophoric features and optimal lipophilic–hydrophilic balance underlie its diverse anticancer therapeutic actions, including cell cycle arrest, apoptosis, ferroptosis, and autophagy activation, alongside metastasis and angiogenesis inhibition. PP7 has gained attention for its potent bioactivity in breast cancer and other pathological conditions. In breast cancer, PP7 demonstrates remarkable efficacy, addressing not only tumor growth but also associated complications such as inflammation and osteoporosis. Additionally, PP7 exhibits synergistic effects with chemotherapeutic agents like cisplatin, bortezomib, and gefitinib, enhancing cancer cell apoptosis and mitigating drug resistance. Beyond its anticancer properties, PP7 also displays broad pharmacological activities, including anti-inflammatory, hepatoprotective, and antimicrobial effects. Thus, PP7 holds significant potential for therapeutic application across breast cancer patients with comorbidities. However, further research is necessary to clarify its specific role in breast cancer subtypes, ensure its safety in clinical applications, and optimize its broad-scale biosynthesis. This review highlights the structure-driven mechanisms underlying PP7 actions and its therapeutic potential as a standalone agent or adjunct in breast cancer therapy.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 7","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70064","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Polyphyllin VII (PP7), a natural saponin derived from the rhizomes of Paris polyphylla (family: Melanthiaceae), possesses a unique steroidal furostane structure that contributes to its versatile pharmacological profile. It is traditionally used in Chinese medicine for treating pain, insect bites, and bleeding. PP7's unique pharmacophoric features and optimal lipophilic–hydrophilic balance underlie its diverse anticancer therapeutic actions, including cell cycle arrest, apoptosis, ferroptosis, and autophagy activation, alongside metastasis and angiogenesis inhibition. PP7 has gained attention for its potent bioactivity in breast cancer and other pathological conditions. In breast cancer, PP7 demonstrates remarkable efficacy, addressing not only tumor growth but also associated complications such as inflammation and osteoporosis. Additionally, PP7 exhibits synergistic effects with chemotherapeutic agents like cisplatin, bortezomib, and gefitinib, enhancing cancer cell apoptosis and mitigating drug resistance. Beyond its anticancer properties, PP7 also displays broad pharmacological activities, including anti-inflammatory, hepatoprotective, and antimicrobial effects. Thus, PP7 holds significant potential for therapeutic application across breast cancer patients with comorbidities. However, further research is necessary to clarify its specific role in breast cancer subtypes, ensure its safety in clinical applications, and optimize its broad-scale biosynthesis. This review highlights the structure-driven mechanisms underlying PP7 actions and its therapeutic potential as a standalone agent or adjunct in breast cancer therapy.

Abstract Image

多叶磷脂VII在乳腺癌治疗中的结构驱动机制和协同途径
多叶黄素VII (PP7)是一种从多叶黄属植物的根状茎中提取的天然皂苷,具有独特的甾体呋喃烷结构,有助于其多种药理作用。它在传统中医中用于治疗疼痛、昆虫叮咬和出血。PP7独特的药效特性和最佳的亲脂-亲水平衡是其多种抗癌治疗作用的基础,包括细胞周期阻滞、细胞凋亡、铁凋亡和自噬激活,以及转移和血管生成抑制。PP7因其在乳腺癌和其他病理疾病中的强大生物活性而受到关注。在乳腺癌中,PP7显示出显著的疗效,不仅可以解决肿瘤生长,还可以解决炎症和骨质疏松等相关并发症。此外,PP7与顺铂、硼替佐米、吉非替尼等化疗药物具有协同作用,促进癌细胞凋亡,减轻耐药。除了抗癌特性,PP7还显示出广泛的药理活性,包括抗炎、保护肝脏和抗菌作用。因此,PP7在乳腺癌合并症患者的治疗应用中具有重要的潜力。但其在乳腺癌亚型中的具体作用、临床应用的安全性、大规模生物合成的优化等仍需进一步研究。这篇综述强调了PP7作用的结构驱动机制及其作为独立药物或辅助药物在乳腺癌治疗中的治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信